日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Germline POT1 Variants in a Pan-Cancer Cohort

泛癌队列中的种系 POT1 变异

Brock, Pamela L; Webster, Morgan; Liyanarachchi, Sandya; Byrne, Lindsey; Hedges, Dale J; Gulhati, Pat; Hicks, J Kevin; Chan, Carlos H F; Onel, Kenan; Stout, Leigh Anne; Maxwell, Whitney; Pickarski, Justine Cooper; Estrada-Veras, Juvianee; Salhia, Bodour; Axell, Lisen; Holman, Laura L; Abdel-Rahman, Mohamed H; Ringel, Matthew D

CHEK2 Founder Variants and Thyroid Cancer Risk

CHEK2 创始变异与甲状腺癌风险

Brock, Pamela; Liynarachchi, Sandya; Nieminen, Taina T; Chan, Carlos; Kohlmann, Wendy; Stout, Leigh Anne; Yao, Song; La Greca, Amanda; Jensen, Kirk E; Kolesar, Jill M; Salhia, Bodour; Gulhati, Pat; Hicks, J Kevin; Ringel, Matthew D

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers

血液肿瘤突变负荷会影响免疫检查点抑制剂治疗的乳腺癌和前列腺癌的临床结果。

Barnett, Reagan M; Jang, Albert; Lanka, Sree; Fu, PIngfu; Bucheit, Leslie A; Babiker, Hani; Bryce, Alan; Meyer, Haley M; Choi, Yujin; Moore, Casey; Garje, Rohan; Gao, Xin; Kim, Dae Won; Chang, Richard Y; Gulhati, Pat; Ramaker, Ryne; Bansal, Rani; Zhang, Tian; Oliver Sartor, A; Armstrong, Andrew J; Bilen, Mehmet A; Barata, Pedro

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.

PBRM1 突变可能使胆道癌的一个亚型对靶向 DNA 损伤修复系统的药物敏感

Zimmer Kai, Kocher Florian, Untergasser Gerold, Kircher Brigitte, Amann Arno, Baca Yasmine, Xiu Joanne, Korn W Micheal, Berger Martin D, Lenz Heinz-Josef, Puccini Alberto, Fontana Elisa, Shields Anthony F, Marshall John L, Hall Michael, El-Deiry Wafik S, Hsiehchen David, Macarulla Teresa, Tabernero Josep, Pichler Renate, Khushman Moh'd, Manne Upender, Lou Emil, Wolf Dominik, Sokolova Viktorija, Schnaiter Simon, Zeimet Alain G, Gulhati Pat, Widmann Gerlig, Seeber Andreas

Molecular Landscape of Small Bowel Adenocarcinoma

小肠腺癌的分子图谱

Pandya, Karan; Overman, Michael J; Gulhati, Pat

Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA

CEA阈值变化作为CEA升高转移性结直肠癌患者一线全身治疗后疾病进展的预测指标

Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbut, Niall; Chibaudel, Benoist; Gramont, Aimery De; Shi, Qian; Overman, Michael James

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater

帕尼单抗治疗RAS野生型小肠或乏特壶腹转移性腺癌的II期研究

Gulhati, Pat; Raghav, Kanwal; Shroff, Rachna; Varadhachary, Gauri; Javle, Milind; Qiao, Wei; Wang, Huamin; Morris, Jeffrey; Wolff, Robert; Overman, Michael J

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study

贝伐珠单抗联合卡培他滨和奥沙利铂治疗晚期小肠或乏特壶腹腺癌患者:一项单中心、开放标签的II期研究

Gulhati, Pat; Raghav, Kanwal; Shroff, Rachna T; Varadhachary, Gauri R; Kopetz, Scott; Javle, Milind; Qiao, Wei; Wang, Huamin; Morris, Jeffrey; Wolff, Robert A; Overman, Michael J

An analysis of trends and growth factor receptor expression of GI carcinoid tumors

胃肠道类癌肿瘤趋势及生长因子受体表达分析

Bowen, Kanika A; Silva, Scott R; Johnson, Jessica N; Doan, Hung Q; Jackson, Lindsey N; Gulhati, Pat; Qiu, Suimin; Riall, Taylor S; Evers, B Mark

Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis

Akt2 过表达在结直肠癌转移的发生发展中起着关键作用。

Rychahou, Piotr G; Kang, JungHee; Gulhati, Pat; Doan, Hung Q; Chen, L Andy; Xiao, Shu-Yuan; Chung, Dai H; Evers, B Mark